China's Changing Drug Market In The Wake Of Essential Drugs List
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain
You may also be interested in...
Squeezed by Price Caps And Rising Costs, China's Nepstar Drugstore Chain Pushes Its Own Brands
Want to get beverages on a drug store run for aspirin in China? Not a problem in Nepstar stores, where China's largest retail pharmacy chain is increasingly becoming more of a convenience store than a traditional drug store. It is shifting its business model to focus on private label products to fend off a double squeeze: swelling rental and labor costs and ongoing governmental reform initiatives to impose price caps on drug retailers
Squeezed by Price Caps And Rising Costs, China's Nepstar Drugstore Chain Pushes Its Own Brands
Want to get beverages on a drug store run for aspirin in China? Not a problem in Nepstar stores, where China's largest retail pharmacy chain is increasingly becoming more of a convenience store than a traditional drug store. It is shifting its business model to focus on private label products to fend off a double squeeze: swelling rental and labor costs and ongoing governmental reform initiatives to impose price caps on drug retailers
China's Essential Drug Prices Less Severe Than Expected; Some Prices See Increases
SHANGHAI - China's National Development and Reform Commission issued Oct. 2 a guideline price for its Essential Drug List, which stipulates price ceilings for 296 drugs on the first part of the list